S U M M A R Y Cerebral infarction was produced by unilateral carotid ligation in the gerbil, and 5HT levels in the cerebral hemispheres were assayed 3-5 hours later. A bilateral fall was confirmed, with the greatest change occurring on the side of carotid ligation in animals showing the clinical sequelae of infarction. Neither absolute levels nor right left differences in 5HT content related directly to the nature or prevalence of neurological morbidity. Neither putative 5HT receptor antagonists nor agents causing increasing brain 5HT levels produced consistent changes in the prevalence of neurological morbidity. It is argued that the fall in 5HT in a cerebral infarct is more likely to be due to reduced synthesis and turnover than to release of the amine into the synaptic cleft. These findings cast doubt on the hypothesis that a significant part of the morbidity and mortality of cerebral infarction is due to the sequelae of 5HT release.
It has been suggested that changes in neurotransmitters in ischaemic brain have secondary deleterious effects on cerebral blood flow and metabolism.' In particular the levels of 5-hydroxytryptamine (5HT) have been shown to fall in experimental models of cerebral ischaemia,2 3 and are low also in human cerebral infarcts at autopsy.4 In order to investigate the possible relevance of 5HT changes to the clinical sequelae of cerebral infarction, and to explore the effects of pharmacological intervention, a further study in the gerbil stroke model has been carried out.
Methods
Cerebral ischaemia was produced by unilateral ligation of the common carotid artery through a midline cervical incision under pentobarbitone (50 mgm/ Kg ip) anaesthesia. Sham operated animals served as controls.
Clinical signs of cerebral infarction were elicited on recovery from anaesthesia. Animals were classed as showing normal behaviour, as having splayed contralateral limbs, or as having been seen to be circling or to have rolling seizures. Some animals were killed by decapitation at 3.5
hours after surgery for assay of cerebral hemisphere 5HT content. The brain was rapidly removed and placed on a cooled plate. The right and left cerebral hemispheres were then dissected, weighed and separately homogenised prior to assay by the method of Curzon and Green.5 Other animals were followed for 24 hours to confirm the clinical observations made in the first post-operative hours and then killed for histological examination (Dr P Lantos).
To study the relevance of 5HT levels, groups of animals were given (by intraperitoneal injection) the following materials designed to depress or elevate whole brain SHT, or to block 5HT receptors. The 5HT levels after the various drug treatments are shown in the figure. As expected, levels in sham operated animals were elevated after preloading with L-tryptophan after pargyline, and after 5-hydroxy-l-tryptophan, and were depleted after 48 hours administration of pCPA which inhibits tryptophan hydroxylase. (The rather modest elevation of 5HT after L-tryptophan may in retrospect be attributable to the small dose of monoamine oxidase inhibitor employed). The putative 5HT antagonists methysergide, BW 501C and cyproheptidine had no effect on 5HT level. Quipazine and methergoline both increased hemisphere 5HT content. The effect of surgery was obvious in nearly all the treated groups with an approximately 30% fall in 5HT content in the ipsilateral hemisphere of clinically affected animals. The exceptions were in the group given 5-hydroxy-l-tryptophan in whom the fall (from a very high level) was small and for those given pCPA where the fall (from a lower than normal level) was greater (approximately 50% Right-left differences in hemispheric levels of 5HT showed no simple correlation with prevalence of neurological signs in the different groups. High or low proportions of affected animals were seen with or without a significant right left difference (table 4) .
After the more extended period of neurological observation (24 hours) more animals were affected with a higher mortality after L-tryptophan and quipazine. None of the other agents caused a significant departure from the control data (table 5) . The combined mortality for all those animals given agents causing elevated brain 5HT (n =113) was 44% (controls 18% p<001). The proportion with neurological signs, fatal or not, was 62-5% (controls 31% p<0-001). The combined morbidity and mortality among groups given methysergide, BW 501C or cyproheptidine (n = 104) was unchanged from control values (mortality 16%, combined morbidity and mortality 34%). Histological examination showed evidence of infarction in 32 of 33 clinically affected animals, and in none of 10 animals whose motor behaviour was normal.
Combining the 3-5 hour and 24 hour data reveals an overall morbidity and mortality in controls of 40 5% (n = 79). With elevated 5HT (Ltryptophan, 5OH-L-tryptophan, quipazine, methergoline; n=185) 53% were affected (x2=34 ns). closely with histological evidence of infarction. It can be concluded that the 5HT change is related to infarction rather than to seizure activity (which has been shown to be the major cause of changes in dopamine and norepinephrine levels in this model).
Role of 5HT in the morbidity of cerebral infarction-a study in the gerbil stroke model It has been suggested that the fall in 5HT accompanying infarction is due to release into the synaptic cleft where it may have behavioural sequelae, and/or into the vicinity of blood vessels where it might aggravate the extent and depth of ischaemia by provoking secondary vasoconstriction. In a previous study we showed that cerebral 5HIAA levels had fallen [3] [4] [5] hours after carotid ligation in the gerbil,2 and we argued that reduced activity in median raphe serotinergic neurones could explain the bilateral change in 5HT and its metabolite. There was no need to invoke synaptic release. The present finding that a 30% fall in 5HT occurs even after L-tryptophan and pargyline favours the view that 5HT synthesis is impaired. The finding that the post operative fall is largely overridden by pre-loading animals with 5-hydroxy-1-tryptophan can be taken as further evidence that the fall in 5HT due to infarction is specific to changes in serotonergic neurones. Low 5HT and 5HIAA levels also have been found in acute cerebral infarcts in man, together with elevated levels of tryptophan in the necrotic area.4 These changes again support the concept of reduced synthesis and turnover of 5HT in infarcted tissue. In perifocal oedematous white matter tryptophan, 5HT and 5HIAA levels were all elevated, perhaps reflecting impaired transport out of the infarcted area. If impaired synthesis, rather than release, is the cause of the fall in 5HT the clinical relevance of the change might not be as important as claimed previously.
It seems unlikely from the results of the present study that either absolute levels of 5HT or rightleft differences in hemisphere content have a major influence on the motor behaviour of the animals after carotid ligation. Similarly receptor antagonists, including those with central effects failed to produce a striking change in the prevalence of neurological morbidity. Although a small but significant reduction in neurological changes was seen with BW 501C and with the group of putative receptor antagonists as a whole at 3.5 hours, the combined data including the 24 hour clinical observations showed no such difference. Again though some increased mortality accompanied 5-hydroxytryptophan and L-tryptophan in the 24 hours observation period, the combined data with larger numbers showed no significant exacerbation of clinical sequelae by these drugs.
The conclusion of the present series of experiments must be that there is no simple link between 5HT levels in ischaemic brain and clinical sequelae. Only a clinical trial, however, could show 
